UNSPSC 51373436: Citric/codeine/ipecac/potassium/promethazine/sodium citrate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373436 Citric/codeine/ipecac/potassium/promethazine/sodium citrate is a Commodity code that in recent state and local solicitations covers pharmaceutical supply contracts — principally opioid-reversal agents and generic multi-source drugs procured for public health systems and cooperative purchasing consortia. State and local buyers in this space are county health departments and multi-state cooperative purchasing alliances that aggregate demand for pharmaceuticals and over-the-counter products across multiple participating jurisdictions and facilities. The work involves establishing frameworks for competitive supply of branded and generic pharmaceuticals, often with quarterly or annual delivery schedules to public health buildings, clinics, or authorized wholesaler distribution networks. Vendors must meet strict regulatory compliance including cGMP certification, Drug Supply Chain Security Act adherence, FDA registration, and often carry significant insurance requirements in the range of $2 million to $5 million for commercial general liability and professional liability coverage.

Recent activity appears concentrated in the Southeast and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a July 26, 2023 response deadline, funded potentially through FEMA and requiring quarterly deliveries with vendor-assumed shipping costs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for multiple contracts supplying generic pharmaceuticals and OTC products across participating states including Oregon, with a March 26, 2026 proposal deadline and effective date of July 1, 2026. The MMCAP procurement emphasizes price competitiveness (weighted at 75 percent in evaluation) and mandates vendor relationships with at least two of three specified authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC — with chargeback systems and EDI capability required.